World's Best Scientists 2026 revealed!
Ignace Vergote

Ignace Vergote

D-Index & Metrics

Medicine

D-Index
147
Citations
101658
World Ranking
1261
National Ranking
14

Overview

Ignace Vergote is affiliated with KU Leuven in Belgium and has an extensive publication record in the fields of medicine and molecular biology, with a focus on oncology, reproductive medicine, and obstetrics and gynecology. Their research spans multiple subfields including genetics and molecular biology.

The scientist's primary research topics include ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, and endometrial and cervical cancer treatments. Other significant areas of work are BRCA gene mutations in cancer, cancer immunotherapy and biomarkers, intraperitoneal and appendiceal malignancies, and cervical cancer and HPV research.

Among the recent papers published by Ignace Vergote are:

  • "ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma," 2020, International Journal of Gynecological Cancer
  • "A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling," 2020, Cell Research
  • "Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial," 2021, The Lancet Oncology
  • "Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study," 2021, The Lancet Oncology
  • "Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial," 2023, Annals of Oncology

Ignace Vergote frequently collaborates with other researchers in the field. The top co-authors include Jalid Sehouli, Nicoletta Colombo, Domenica Lorusso, Toon Van Gorp, and David Cibula.

The scientist's work is widely disseminated through key journals such as:

  • International Journal of Gynecological Cancer
  • Journal of Clinical Oncology
  • Gynecologic Oncology
  • Annals of Oncology
  • European Journal of Cancer

Through these research contributions, Ignace Vergote has a significant presence in domains exploring cancer biology, particularly focusing on clinical and molecular mechanisms underlying gynecological cancers. Their research output reflects engagement with advancing therapeutic approaches and clinical guidelines relevant to cancer treatment protocols.

Best Publications

  • Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

    Ignace Vergote;Claes G. Tropé;Frédéric Amant;Gunnar B. Kristensen

  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Mansoor R. Mirza;Bradley J. Monk;Jørn Herrstedt;Amit M. Oza

  • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

    Eric Pujade-Lauraine;Felix Hilpert;Beatrice Weber;Alexander Reuss

  • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Antonio González-Martín;Bhavana Pothuri;Ignace Vergote;René DePont Christensen

  • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    Isabelle Ray-Coquard;Patricia Pautier;Sandro Pignata;David Pérol

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

    Nicole Concin;Xavier Matias-Guiu;Ignace Vergote;David Cibula

  • Epithelial Ovarian Cancer

    Stephanie Lheureux;Charlie Gourley;Ignace Vergote;Amit M Oza

  • Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Antonio González-Martín;Bhavana Pothuri;Ignace Vergote;René De Pont Christensen

  • Randomized Intergroup Trial of Cisplatin–Paclitaxel Versus Cisplatin–Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

    Martine J. Piccart;Kamma Bertelsen;Keith James;Jim Cassidy

  • Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

    J Bonneterre;B Thurlimann;J Robertson;M Krzakowski

  • Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group

    Dirk Timmerman;L Valentin;Tom Bourne;W P Collins

  • Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

    Jacobus Pfisterer;Marie Plante;Ignace Vergote;Andreas du Bois

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    N. Colombo;C. Sessa;A. du Bois;J. Ledermann

  • Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

    Ganna Chornokur;Hui-Yi Lin;Jonathan P. Tyrer;Kate Lawrenson

  • Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer

    Ate G. J. Van der Zee;Maaike H. Oonk;Joanne A. De Hullu;Anca C. Ansink

  • Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment

    Anthony Howell;John F R Robertson;J Quaresma Albano;A Aschermannova

Frequent Co-Authors

Patrick Neven
Patrick Neven KU Leuven
Jalid Sehouli
Jalid Sehouli Charité - University Medicine Berlin
Andreas du Bois
Andreas du Bois Johannes Gutenberg University of Mainz
Hans Wildiers
Hans Wildiers KU Leuven
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Beth Y. Karlan
Beth Y. Karlan University of California, Los Angeles
Ian G. Campbell
Ian G. Campbell Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career doesn’t always follow a traditional route. Online degrees now provide flexible and affordable options to launch or advance a healthcare career. For those looking to start quickly, an lpn accelerated program can prepare you for entry-level nursing roles in as little as a year.

Already have a BSN? Advancing your practice is possible through bsn to np programs online, which let you specialize in in-demand fields such as psychiatric or family nurse practitioner roles. These programs combine flexibility with rigorous clinical training.

For those interested in the business side of healthcare, an online healthcare administration degree offers essential management and organizational skills. Graduate degrees, like a Master of Healthcare Administration, are also available online, and the cost of mha degree varies widely depending on the program and institution.

Whether you’re aiming for clinical or administrative roles, these pathways make it easier to reach your goals at your own pace—and often at a fraction of the cost of traditional campus-based programs.

Best Scientists Citing Ignace Vergote

Trending Scientists

Recently Published Articles